You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: April 19, 2024

Claims for Patent: 6,951,219

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 6,951,219

Title:	Treatment of hepatitis C using hyperthermia
Abstract:	The invention provides a method of treating a patient infected with hepatitis C virus (HCV) comprising raising the core temperature of the patient and then returning the core temperature of the patient to normal at least one time, wherein the core temperature is raised to a temperature range and a duration sufficient to reduce or eliminate the patient\'s viral load of HCV.
Inventor(s):	Groth; Karl Emil (St. Paul, MN), Kelly; Theodore Charles (Minnetonka, MN), Westerbeck; Todd L. (Burnsville, MN), Blick; Gary (Stamford, CT)
Assignee:	First Circle Medical, Inc. (Minneapolis, MN)
Application Number:	10/667,917
Patent Claims:	1. A method for treating a patient infected with hepatitis C virus (HCV) comprising raising the core temperature of the patient and then returning the core temperature of the patient to normal at least one time, wherein the core temperature is raised to a temperature range and a duration sufficient to reduce the patient's viral load of HCV by 30 percent or more three months after the core temperature has been raised and returned to normal said at least one time, wherein the patient's viral load of HCV is determined at least once after the core temperature has been raised and returned to normal said at least one time, and wherein the patient is treated with a pharmaceutical indicated for hepatitis C that is selected from ribavirin, lamivudine, interferon alfacon-1, interferon alfa-2a, interferon alfa-2b, interferon-alfa-n1, thymosin alpha-1, interleukin-2, interferon alpha-n3, ketoprofen, interferon beta-1a, interferon gamma-1b, interleukin-12, or combinations thereof. 2. A method according to claim 1, wherein the pharmaceutical is ribavirin. 3. A method according to claim 1, wherein the pharmaceutical is lamivudine. 4. A method according to claim 1, wherein the pharmaceutical is interferon alfacon-1. 5. A method according to claim 1, wherein the pharmaceutical is interferon alfa-2a. 6. A method according to claim 1, wherein the pharmaceutical is interferon alfa-2b. 7. A method according to claim 1, wherein the pharmaceutical is interferon-alfa-n1. 8. A method according to claim 1, wherein the pharmaceutical is thymosin alpha-1. 9. A method according to claim 1, wherein the pharmaceutical is interleukin-2. 10. A method according to claim 1, wherein the pharmaceutical is interferon alpha-n3. 11. A method according to claim 1, wherein the pharmaceutical is ketoprofen. 12. A method according to claim 1, wherein the pharmaceutical is interferon beta-1a. 13. A method according to claim 1, wherein the pharmaceutical is interferon gamma-1b. 14. A method according to claim 1, wherein the pharmaceutical is interleukin-12. 15. A method for treating a patient infected with hepatitis C virus (HCV) comprising raising the core temperature of the patient and then returning the core temperature of the patient to normal at least one time, wherein the core temperature is raised to a temperature range and a duration sufficient to reduce the patient's viral load of HCV by 30 percent or more one month after the core temperature has been raised and returned to normal said at least one time, wherein the patient's viral load of HCV is determined at least once after the core temperature has been raised and returned to normal said at least one time, and wherein the patient is treated with a pharmaceutical indicated for hepatitis C that is selected from ribavirin, lamivudine, interferon alfacon-1, interferon alfa-2a, interferon alfa-2b, interferon-alfa-n1, thymosin alpha-1, interleukin-2, interferon alpha-n3, ketoprofen, interferon beta-1a, interferon gamma-1b, interleukin-12, or combinations thereof. 16. A method according to claim 15, wherein the pharmaceutical is ribavirin. 17. A method according to claim 15, wherein the pharmaceutical is lamivudine. 18. A method according to claim 15, wherein the pharmaceutical is interferon alfacon-1. 19. A method according to claim 15, wherein the pharmaceutical is interferon alfa-2a. 20. A method according to claim 15, wherein the pharmaceutical is interferon alfa-2b. 21. A method according to claim 15, wherein the pharmaceutical is interferon-alfa-n1. 22. A method according to claim 15, wherein the pharmaceutical is thymosin alpha-1. 23. A method according to claim 15, wherein the pharmaceutical is interleukin-2. 24. A method according to claim 15, wherein the pharmaceutical is interferon alpha-n3. 25. A method according to claim 15, wherein the pharmaceutical is ketoprofen. 26. A method according to claim 15, wherein the pharmaceutical is interferon beta-1a. 27. A method according to claim 15, wherein the pharmaceutical is interferon gamma-1b. 28. A method according to claim 15, wherein the pharmaceutical is interleukin-12. 29. A method for treating a patient infected with hepatitis C virus (HCV) comprising raising the temperature of the patient's liver and then returning the temperature of the patient's liver to normal at least one time, wherein the temperature of the patient's liver is raised to a temperature range and a duration sufficient to reduce the patients viral load of HCV by 30 percent or more three months after the temperature of the patient's liver has been raised and returned to normal said at least one time, wherein the patient's viral load of HCV is determined at least once after the temperature of the patient's liver has been raised and returned to normal said at least one time, and wherein the patient is treated with a pharmaceutical indicated for hepatitis C that is selected from ribavirin, lamivudine, interferon alfacon-l, interferon alfa-2a, interferon alfa-2b, interferon-alfa-n1, thymosin, interleukin-2, interferon alpha-n3, ketoprofen, interferon beta-1a, interferon gamma-1b, interleukin-12, or combinations thereof. 30. A method according to claim 29, wherein the pharmaceutical is ribavirin. 31. A method according to claim 29, wherein the pharmaceutical is lamivudine. 32. A method according to claim 29, wherein the pharmaceutical is interferon alfacon-1. 33. A method according to claim 29, wherein the pharmaceutical is interferon alfa-2a. 34. A method according to claim 29, wherein the pharmaceutical is interferon alfa-2b. 35. A method according to claim 29, wherein the pharmaceutical is interferon-alfa-n1. 36. A method according to claim 29, wherein the pharmaceutical is thymosin alpha-1. 37. A method according to claim 29, wherein the pharmaceutical is interleukin-2. 38. A method according to claim 29, wherein the pharmaceutical is interferon alpha-n3. 39. A method according to claim 29, wherein the pharmaceutical is ketoprofen. 40. A method according to claim 29, wherein the pharmaceutical is interferon beta-1a. 41. A method according to clam 29, wherein the pharmaceutical is interferon gamma-1b. 42. A method according to claim 29, wherein the pharmaceutical is interleukin-12. 43. A method for treating a patient infected with hepatitis C virus (HCV) comprising raising the temperature of the patient's liver and then returning the temperature of the patient's liver to normal at least one time, wherein the temperature of the patient's liver is raised to a temperature range and a duration sufficient to reduce the patient's viral load of HCV by 30 percent or more one month after the temperature of the patient's liver has been raised and returned to normal said at least one time, wherein the patient's viral load of HCV is determined at least once after the temperature of the patient's liver has been raised and returned to normal said at least one time, and wherein the patient is treated with a pharmaceutical indicated for hepatitis C that is selected from ribavirin, lamivudine, interferon alfacon-1, interferon alfa-2a, interferon alfa-2b, interferon-alfa-n1, thymosin alpha-1, interleukin-2, interferon alpha-n3, ketoprofen, interferon beta-1a, interferon gamma-1b, interleukin-12, or combinations thereof. 44. A method according to claim 43, wherein the pharmaceutical is ribavirin. 45. A method according to claim 43, wherein the pharmaceutical is lamivudine. 46. A method according to claim 43, wherein the pharmaceutical is interferon alfacon-1. 47. A method according to claim 43, wherein the,pharmaceutical is interferon alfa-2a. 48. A method according to claim 43, wherein the pharmaceutical is interferon alfa-2b. 49. A method according to claim 43, wherein the pharmaceutical is interferon-alfa-n1. 50. A method according to claim 43, wherein the pharmaceutical is thymosin alpha-1. 51. A method according to claim 43, wherein the pharmaceutical is interleukin-2. 52. A method according to claim 43, wherein the pharmaceutical is interferon alpha-n3. 53. A method according to claim 43, wherein the pharmaceutical is ketoprofen. 54. A method according to claim 43, wherein the pharmaceutical is interferon beta-1a. 55. A method according to claim 43, wherein the pharmaceutical is interferon gamma-1b. 56. A method according to claim 43, wherein the pharmaceutical is interleukin-12.

Details for Patent 6,951,219

Subscribe to access the full database, or Try a Trial
Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132	06/04/1986	⤷ Try a Trial	2020-01-14
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132		⤷ Try a Trial	2020-01-14
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	Injection	103132		⤷ Try a Trial	2020-01-14
Biogen Inc.	AVONEX	interferon beta-1a	For Injection	103628	05/17/1996	⤷ Try a Trial	2020-01-14
Biogen Inc.	AVONEX	interferon beta-1a	Injection	103628	05/28/2003	⤷ Try a Trial	2020-01-14
Biogen Inc.	AVONEX	interferon beta-1a	Injection	103628	02/27/2012	⤷ Try a Trial	2020-01-14
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Approval Date	>Patent No.	>Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.